Table 2.

Parameter estimates for final population PK model

Parameter	Final Value	SE	Median Bootstrap Estimate* (95% Confidence Interval)
Θ1 (EH)	0.14	0.03	0.15 (0.10 – 0.22)
Θ2 (VD)	1.61	0.34	1.63 (1.04 – 2.5)
Θ3 (KA)	0.31	0.06	0.31 (0.15 – 0.40)
Θ4 (Tablet)	1.23	0.11	1.23 (1.03 – 1.47)
Θ5** (Maturation Effect on F)	0.97	0.46	1.09 (0.57 – 2.28)
Θ6** (Half-life of Maturation)	0.98	0.63	0.97 (0.02 – 6.90)
Between Subject Variability (BSV)**
BSV, EH	42%	2%	41% (35% - 47%)
BSV, VD	48%	3%	71% (57% −82%)
BSV interaction, (EH-VD)	38%	2%	47% (41% - 53%)
Error
Proportional	9.4%	0.03	9.6% (0.4% - 15.2%)
Additive (μg/mL)	2.13	0.16	2.11 (1.71–2.40)
EH =Θ1 CL (L/hr) = EH • QHP VD (L) = Θ2 • WT KA (1/hr) = Θ3
QHP (L/hr) = ${50•\left(\frac{WT}{70}\right)}^{0.75}$ $\text{F}=\left(1-\text{EH}\right)•{\Theta }_4{}^{Formulation}•\left(1+{\Theta }_5\left(1-{\text{e}}^{-\left(\text{AGEY}-0.115\right){\Theta }_6}\right)\right)$

^*Bootstrap had a convergence rate of 85.1%.

^**Plateau Maturation Effect is represented by both Maturation Effect on F_ABS (Θ₅) and Half-life of Maturation (Θ₆)

^***BSV was not assessed on F_ABS or KA.

^****F represents relative bioavailability with a reference value F=1 for an infant 0.115 years of age receiving the liquid formulation